Advocacy intelligence hub — real-time data for patient organizations
New York Stem Cell Foundation Research Institute
Pharnext S.C.A. — PHASE3
Hereditary Neuropathy Foundation
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons news →
View all Autosomal dominant Charcot-Marie-Tooth disease type 2 with giant axons specialists →